Table 4 Association of clinical activity with tumor biomarkers.
Biomarker | Observed Effect | P- value* | |
|---|---|---|---|
| Â | Benefit Group (n = 21) | Non-benefit Group (n = 43) | Â |
TILs change from baseline to week 4, by H&E | 4/7 increase 0/7 decrease 3/7 no change | 2/20 increase 3/20 decrease 15/20 no change | 0.005 |
FoxP3 expression at baseline, by IHC | 6/8 evaluable patients positive | 9/25 evaluable patients positive | 0.014 |
IDO expression at baseline, by IHC | 3/8 evaluable patients positive | 3/27 evaluable patients positive | 0.012 |